Clinical Trial

Glucotrack Announces Reverse Stock Split Shareholder Approved Action Meets NASDAQ Panel Hearing Listing Requirements

1-for-60 reverse stock split to become effective as of the opening of trading on June 16, 2025 Rutherford, NJ, June…

7 months ago

Fortrea Adopts Limited-Duration Stockholder Rights Plan

Board Committed to Protecting Long-Term Value for All StockholdersDURHAM, N.C., June 12, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the…

7 months ago

Fortrea Adopts Limited-Duration Stockholder Rights Plan

Board Committed to Protecting Long-Term Value for All StockholdersDURHAM, N.C., June 12, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the…

7 months ago

Rakovina Therapeutics to Attend BIO International Convention to Advance Strategic Partnering Opportunities

VANCOUVER, British Columbia, June 12, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”),…

7 months ago

AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen®

Patent portfolio now includes protection for manufacture, methods and compositions Provides AIM with patent protection for manufacturing Ampligen until 2041…

7 months ago

Rakovina Therapeutics to Attend BIO International Convention to Advance Strategic Partnering Opportunities

VANCOUVER, British Columbia, June 12, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”),…

7 months ago

Rakovina Therapeutics to Attend BIO International Convention to Advance Strategic Partnering Opportunities

VANCOUVER, British Columbia, June 12, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”),…

7 months ago

Prenetics Announces First Quarter 2025 Financial Results, Raises FY2025 Outlook, & Crypto Strategy Announcement Soon

Revenue grew 336.5% to $14.4 million from prior year (excluding ACT Genomics)Raises full year revenue outlook to $80 - $100…

7 months ago

Prenetics Announces First Quarter 2025 Financial Results, Raises FY2025 Outlook, & Crypto Strategy Announcement Soon

Revenue grew 336.5% to $14.4 million from prior year (excluding ACT Genomics)Raises full year revenue outlook to $80 - $100…

7 months ago

Prenetics Announces First Quarter 2025 Financial Results, Raises FY2025 Outlook, & Crypto Strategy Announcement Soon

Revenue grew 336.5% to $14.4 million from prior year (excluding ACT Genomics)Raises full year revenue outlook to $80 - $100…

7 months ago